V. Torri

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
V Torri, V. Torri, Valter Torri
Publication record
433 papers · 34,838 citations · H-index 80

PAPERS

Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey
20238 citationsauthor #20
First line combination of ribociclib and letrozole in patients (pts) with metastatic breast cancer (MBC): Focus on hepatic toxicity in the context of a real–world setting the Italian, multicenter Hermione–8 study.
20231 citationsauthor #15
Centre for Statistical and Methodological Excellence (CESAME): A Consortium Initiative for Improving Methodology in Randomised Clinical Trials
20230 citationsauthor #17
Radiosurgery of limited brain metastases from primary solid tumor: results of the randomized phase III trial (NCT02355613) comparing treatments executed with a specialized or a C-arm linac-based platform
202316 citationsauthor #9
DESTINY-Breast03 trial: some questions remain.
20230 citationsauthor #4
Oxaliplatin prior to PARP inhibitor in BRCA-mutated ovarian cancer
20231 citationsauthor #9
A systematic review and meta-analysis on the Optimal Treatment duration of cHEckpoint inhibitoRS in solid tumors: the OTHERS study.
202320 citationsauthor #17
Immunometabolic interference between cancer and COVID-19
20233 citationsauthor #14
Improving Outcome of Selected Patients With Non-Resectable Hepatic Metastases From Colorectal Cancer With Liver Transplantation: A Prospective Parallel Trial (COLT trial).
20238 citationsauthor #20
Guideline Application in Real world: multi-Institutional Based survey of Adjuvant and first-Line pancreatic Ductal adenocarcinoma treatment in Italy. Primary analysis of the GARIBALDI survey
20238 citationsauthor #153
Final results of the real-life observational VICTOR-6 study on metronomic chemotherapy in elderly metastatic breast cancer (MBC) patients
20235 citationsauthor #45
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
202318 citationsauthor #32
Stereotactic body radiation therapy (SBRT) for lung metastases from sarcoma in oligometastatic patients: a phase 2 study.
202227 citationsauthor #9
Circulating CD81-expressing extracellular vesicles as biomarkers of response for immune-checkpoint inhibitors in advanced NSCLC
202215 citationsauthor #18
Phase III study to compare bevacizumab or cetuximab plus FOLFIRI in patients with advanced colorectal cancer RAS/BRAF wild type (wt) on tumor tissue and RAS mutated (mut) in liquid biopsy: LIBImAb Study.
20221 citationsauthor #6
Tumor‐associated macrophages and risk of recurrence in stage III colorectal cancer
202217 citationsauthor #12
A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry
202219 citationsauthor #71
How Age, Comorbidities and Concomitant Medications Influence Ibrutinib Management and Survival in Waldenstrom Macroglobulinemia
20221 citationsauthor #27
Circulating tumor DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial
2022194 citationsauthor #16
Tolerability of Eribulin and correlation between polymorphisms and neuropathy in an unselected population of female patients with metastatic breast cancer: results of the multicenter, single arm, phase IV PAINTER study
20223 citationsauthor #25
Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis
202216 citationsauthor #3
Circulating Fatty Acid Profile as a Biomarker for Immunotherapy in Advanced Non-Small Cell Lung Cancer.
202210 citationsauthor #21
A systematic review and meta-analysis of early death (ED) upon immune checkpoint inhibitors (ICI) alone or combined with other non-ICIs treatments as first-line treatment of advanced solid tumors.
20220 citationsauthor #19
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis.
2022147 citationsauthor #26
2022-RA-760-ESGO Predictive model of severe complications in patients who underwent an open gynecological cancer surgery on an enhanced recovery after surgery (ERAS) program
20220 citationsauthor #13
Bevacizumab for advanced ovarian cancer treatment. A GRADE based approach
20220 citationsauthor #2
PEOPLE (NTC03447678), a phase II trial of first-line, single-agent pembrolizumab in advanced NSCLC with low PD-L1: Clinical outcomes and association with circulating immune biomarkers.
20220 citationsauthor #16
Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in colorectal carcinoma at high risk of peritoneal carcinomatosis: short-term and long-term outcomes from the CHECK study – protocol for a randomised, multicentre, phase 3 trial
20223 citationsauthor #8
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.
202151 citationsauthor #20
Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.
202150 citationsauthor #13
PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results
20213 citationsauthor #32
SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in Lombardy, Italy
202121 citationsauthor #3
Heme catabolism by tumor-associated macrophages controls metastasis formation
202197 citationsauthor #21
P09.18 COVID-19 Outcomes in Patients With Thoracic Malignancies According to Gender and Ethnicity (TERAVOLT)
20211 citationsauthor #3
"Re-irradiation for recurrent high grade glioma (HGG) patients: results of a single arm prospective phase 2 study. ".
202127 citationsauthor #14
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer
2021216 citationsauthor #35
Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
202174 citationsauthor #59
Prognostic value of CT integrated with clinical and laboratory data during the first peak of the COVID-19 pandemic in Northern Italy: A nomogram to predict unfavorable outcome
202118 citationsauthor #8
1830P Early deaths (ED) upon first-line immunecheckpoint inhibitors (ICI) alone or combined to other non-ICI drugs across solid cancers: A systematic review and meta-analysis
20210 citationsauthor #19
Correction to: Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)
20202 citationsauthor #27
1562P Observational prospective study of Italian guidelines application for patients with pancreatic ductal adenocarcinoma
20200 citationsauthor #17
SARS-CoV-2 serology in 4000 health care and administrative staff across seven sites in 1 Lombardy , Italy 2 3
20200 citationsauthor #3
Correlation of longtime efficacy maintenance PARP inhibitor therapy with pre-treatment in a single-institution experience.
20200 citationsauthor #7
Abstract S12-03: Thoracic cancers international COVID-19 collaboration (TERAVOLT): Small-cell lung cancer and other rare thoracic malignancies
20201 citationsauthor #19
Abstract CT263: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients: The PEGASUS trial
20202 citationsauthor #9
Assessment of assumptions of statistical analysis methods in randomised clinical trials: the what and how
202043 citationsauthor #8
DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation.
20205 citationsauthor #20
507P Central nervous system recurrence in HER2-positive metastatic colorectal cancer
20202 citationsauthor #12
1388P Poziotinib in advanced NSCLC with EGFR or HER2 exon 20 insertion mutation: Initial results from a single site expanded access program
20206 citationsauthor #19
Supporting Clinical Decision-Making during the SARS-CoV-2 Pandemic through a Global Research Commitment: The TERAVOLT Experience
202010 citationsauthor #4
Late Breaking Abstract - Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival
20200 citationsauthor #4
Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial
2020154 citationsauthor #16
Trabectedin in Malignant Pleural Mesothelioma: Results From the Multicentre, Single Arm, Phase II ATREUS Study.
20209 citationsauthor #10
Early progression of disease predicts shorter survival in patients with mucosa-associated lymphoid tissue lymphoma receiving systemic treatment
20205 citationsauthor #4
The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients.
202029 citationsauthor #16
Standard (8 weeks) vs long (12 weeks) Timing to Minimally-Invasive Surgery after NeoAdjuvant Chemoradiotherapy for Rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)
20200 citationsauthor #15
To Continue or Not to Continue? That Is the Question.
20200 citationsauthor #3
Factors Affecting Mortality in 1022 COVID-19 Patients Referred to an Emergency Department in Bergamo during the Peak of the Pandemic
20203 citationsauthor #5
Diagnostic and prognostic values of PBMC proteins in amyotrophic lateral sclerosis.
202027 citationsauthor #4
861P Limited implementation of the ESMO-ESGO (European Society of Gynaecological Oncology)-ESTRO (European Society for Radiotherapy and Oncology) consensus conference recommendations (CCR) on endometrial cancer (EC)
20201 citationsauthor #8
Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials.
2020196 citationsauthor #16
COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study
2020495 citationsauthor #5
Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study
202012 citationsauthor #6
IgG serology in health care and administrative staff populations from 7 hospital representative of different exposures to SARS-CoV-2 in Lombardy, Italy
202031 citationsauthor #3
Immunometabolic Status of COVID-19 Cancer Patients
202030 citationsauthor #6
Turn off pain: What has changed 4 years later?
20200 citationsauthor #6
Early progression of disease predicts shorter survival in MALT lymphoma patients receiving systemic treatment.
202039 citationsauthor #4
Expression levels of circulating miRNAs as biomarkers during multimodal treatment of rectal cancer - TiMiSNAR-mirna: a substudy of the TiMiSNAR Trial (NCT03962088)
20207 citationsauthor #31
TERAVOLT: Thoracic Cancers International COVID-19 Collaboration
202062 citationsauthor #3
Evaluation of a Primary Open-Angle Glaucoma Prediction Model Using Long-term Intraocular Pressure Variability Data: A Secondary Analysis of 2 Randomized Clinical Trials.
202017 citationsauthor #8
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer.
202089 citationsauthor #16
Integrating clinical and biological prognostic biomarkers in patients with advanced NSCLC treated with immunotherapy: the DEMo score system
20209 citationsauthor #14
Implementing clinical practice guidelines: time to assess it
20200 citationsauthor #10
Author Correction: Visual field loss and vision-related quality of life in the Italian Primary Open Angle Glaucoma Study
20201 citationsauthor #9
LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial
20205 citationsauthor #16
Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival.
202049 citationsauthor #3
Abstract CT261: METAMECH -A Master Observational Trial empowering mechanobiology translational research and mechanobased proof of concept trials in breast cancer
20200 citationsauthor #17
Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out.
2019136 citationsauthor #14
DEMo: A prospective evaluation of a prognostic clinico-molecular composite score in NSCLC patients treated with immunotherapy
20190 citationsauthor #15
RE: Presence of Circulating Tumor Cells in High-Risk Early Breast Cancer During Follow-Up and Prognosis.
20191 citationsauthor #2
Assessing assumptions for statistical analyses in randomised clinical trials
201931 citationsauthor #8
HER2 Positivity Predicts Unresponsiveness to EGFR-Targeted Treatment in Metastatic Colorectal Cancer.
2019144 citationsauthor #22
BAROCCO: A randomized phase II study of weekly paclitaxel vs cediranib-olaparib combination given with continuous or intermittent schedule in patients with recurrent platinum resistant ovarian cancer (PROC)
201924 citationsauthor #18
Early progression of disease (POD24) as survival predictor in MALT lymphoma.
20191 citationsauthor #4
Metformin +/- cyclic fasting mimicking diet in combination with platinum-pemetrexed chemotherapy for advanced LKB1 inactive lung adenocarcinoma: The FAME trial.
20191 citationsauthor #19
EARLY PROGRESSION OF DISEASE (POD24) PREDICTS SHORTER SURVIVAL IN MALT LYMPHOMA PATIENTS RECEIVING SYSTEMIC TREATMENT
20192 citationsauthor #4
The prognostic impact of primary tumour location in patients with stage II and stage III colon cancer receiving adjuvant therapy. A GISCAD analysis from three large randomised trials.
201913 citationsauthor #13
Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors
2019184 citationsauthor #11
The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer
20192 citationsauthor #18
Multicenter, randomised, open-label, non-comparative phase 2 trial on the efficacy and safety of the combination of bevacizumab and trabectedin with or without carboplatin in women with partially platinum-sensitive recurrent ovarian cancer
201912 citationsauthor #19
Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
20198 citationsauthor #8
Gadoxetate Disodium-Enhanced MR Cholangiography for Evaluation of Biliary-Enteric Anastomoses: Added Value Beyond Conventional T2-Weighted Images.
20194 citationsauthor #7
Phase II study of pertuzumab and trastuzumab-emtansine (T-DM1) in patients with HER2-positive metastatic colorectal cancer: The HERACLES-B (HER2 Amplification for Colo-rectaL cancer Enhanced Stratification, cohort B) trial
201918 citationsauthor #12
Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1) / Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort
20199 citationsauthor #46
Prospective pooled analysis of four randomized trials investigating duration of adjuvant (adj) oxaliplatin-based therapy (3 vs 6 months {m}) for patients (pts) with high-risk stage II colorectal cancer (CC).
201940 citationsauthor #13
Standard (8 weeks) vs long (12 weeks) timing to minimally-invasive surgery after NeoAdjuvant Chemoradiotherapy for rectal cancer: a multicenter randomized controlled parallel group trial (TiMiSNAR)
20199 citationsauthor #27
EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort
201972 citationsauthor #19
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial.
201914 citationsauthor #21
Combined Low Densities of FoxP3+ and CD3+ Tumor-Infiltrating Lymphocytes Identify Stage II Colorectal Cancer at High Risk of Progression
201934 citationsauthor #16
Multicenter, single arm, phase II trial on the efficacy of ortataxel in recurrent glioblastoma
201922 citationsauthor #9

TIMELINE

1990 98 citations

1991 51 citations

1992 12 citations

1993 57 citations

1994 768 citations

1995 1,103 citations

1996 197 citations

1997 228 citations

1998 5,865 citations

1999 164 citations

2000 408 citations

2001 415 citations

2002 463 citations

2003 2,766 citations

2004 766 citations

2005 863 citations

2006 434 citations

2007 1,411 citations

2008 3,407 citations

2009 2,381 citations

2010 1,896 citations

2011 443 citations

2012 586 citations

2013 906 citations

2014 678 citations

2015 777 citations

2016 1,762 citations

2017 881 citations

2018 1,804 citations

2019 834 citations

2020 1,341 citations

2021 558 citations

2022 453 citations

2023 80 citations

V. Torri

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT